NCT03762031 is a Phase 1 clinical trial of GC4711 30mg in Healthy, sponsored by Galera Therapeutics, Inc..

Who is sponsoring NCT03762031?

NCT03762031 is sponsored by Galera Therapeutics, Inc..

What drugs are being tested in NCT03762031?

Interventions in NCT03762031: GC4711 30mg, GC4711 60mg, GC4711 90mg, GC4711 120mg, Placebo, GC4711 75mg, GC4711 105mg.

Is NCT03762031 still recruiting?

NCT03762031 is currently completed. Last updated 14 August 2020.

Last reviewed 2020-08-14 · How we verify

NCT03762031

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

Completed Phase 1 Last updated 14 August 2020

What this trial tests

Phase 1 trial testing GC4711 30mg in Healthy in 70 participants. Completed in 4 March 2020.

Timeline

19 March 2019

Primary endpoint
4 March 2020

4 March 2020

Quick facts

Lead sponsor	Galera Therapeutics, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	70
Start date	19 March 2019
Primary completion	4 March 2020
Estimated completion	4 March 2020
Sites	1 location across Australia

Drugs / interventions tested

GC4711 30mg — full drug profile →
GC4711 60mg — full drug profile →
GC4711 90mg — full drug profile →
GC4711 120mg — full drug profile →
Placebo
GC4711 75mg
GC4711 105mg — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Galera Therapeutics, Inc. — full company profile →

Who can join

Adults 18 to 50, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will be a Phase 1, randomized, double-blind, placebo-controlled, single dose escalation study designed to evaluate the safety and PK of intravenously administered superoxide dismutase mimetic GC4711 in healthy volunteers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Superoxide Dismutase 1 in Health and Disease: How a Frontline Antioxidant Becomes Neurotoxic.
Trist BG, Hilton JB, Hare DJ, Crouch PJ, et al · · 2021 · cited 148× · PMID 32144830 · DOI 10.1002/anie.202000451
Mitochondrial Oxidative Stress and Cell Death in Podocytopathies.
Zhu YT, Wan C, Lin JH, Hammes HP, et al · · 2022 · cited 31× · PMID 35327595 · DOI 10.3390/biom12030403

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Galera Therapeutics, Inc. trials

Trials by the same sponsor.

NCT04698915 — Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer · Phase 2 · terminated
NCT04476797 — Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC · Phase 1, PHASE2 · terminated
NCT04555096 — A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 · Phase 2 · terminated
NCT04529850 — Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer · Phase 2 · completed
NCT04225026 — Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03762031 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Galera Therapeutics, Inc.
Last refreshed: 14 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03762031.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing